Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience.
Silvia BloiseAlessia MarcellinoBeatrice FrasaccoPietro GizzoneClaudia Proietti CiolliVanessa MartucciMariateresa SansevieroEmanuela Del GiudiceFlavia VentrigliaRiccardo LubranoPublished in: Vaccines (2022)
Our findings confirm the safety of COVID-19 vaccine in children younger 11 years and could be useful to promote its diffusion in pediatric ages in order to achieve "herd immunity" and prevent the virus's circulation.
Keyphrases